Halozyme Therapeutics (HALO) Earnings Date, Estimates & Call Transcripts → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free halo Stock Alerts $40.68 -0.05 (-0.12%) (As of 03/28/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 14EstimatedActual EPS (Feb. 20) $0.75 Missed By -$0.02 Consensus EPS (Feb. 20) $0.77 Get Halozyme Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for HALO and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueHALO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.HALO Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one Halozyme Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20242$0.71$0.77$0.74 Q2 20242$0.74$0.92$0.83 Q3 20242$0.85$0.95$0.90 Q4 20242$0.94$0.97$0.96 FY 20248$3.24$3.61$3.43 Q1 20251$0.85$0.85$0.85 Q2 20251$0.90$0.90$0.90 Q3 20251$0.91$0.91$0.91 Q4 20251$1.15$1.15$1.15 FY 20254$3.81$3.81 $3.81HALO Earnings Date and InformationHalozyme Therapeutics last announced its earnings data on February 20th, 2024. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts' consensus estimates of $0.77 by $0.02. The company earned $230.04 million during the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics has generated $2.11 earnings per share over the last year ($2.11 diluted earnings per share) and currently has a price-to-earnings ratio of 19.3. Earnings for Halozyme Therapeutics are expected to grow by 25.53% in the coming year, from $3.33 to $4.18 per share. Halozyme Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.Read More Halozyme Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/14/2024Estimated)------- 2/20/2024Q4 2023$0.77$0.75($0.02)$0.85$235.25 million$230.04 million11/6/2023Q3 2023$0.67$0.69+$0.02$0.77$219.47 million$216.03 million8/8/2023Q2 2023$0.59$0.68+$0.09$0.80$201.91 million$221.04 million5/9/2023Q1 2023$0.44$0.43($0.01)$0.57$174.20 million$162.14 million2/21/2023Q4 2022$0.43$0.44+$0.01$0.46$186.07 million$181.50 million11/8/2022Q3 2022$0.49$0.70+$0.21$0.96$187.87 million$208.98 million Get the Latest News and Ratings for HALO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/9/2022Q2 2022$0.47$0.50+$0.03$0.84$156.00 million$152.37 million 5/10/2022Q1 2022$0.45$0.43($0.02)$0.43$128.25 million$117.30 million 2/22/2022Q4 2021$0.35$0.39+$0.04$0.32$97.10 million$102.00 million11/2/2021Q3 2021$0.42$1.48+$1.06($0.44)$101.94 million$115.83 million 8/9/2021Q2 2021$0.43$0.62+$0.19$0.64$104.08 million$136.50 million 5/10/2021Q1 2021$0.32$0.37+$0.05$0.49$84.88 million$89.02 million Halozyme Therapeutics Earnings - Frequently Asked Questions When is Halozyme Therapeutics's earnings date? Halozyme Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on HALO's earnings history. Did Halozyme Therapeutics beat their earnings estimates last quarter? In the previous quarter, Halozyme Therapeutics (NASDAQ:HALO) missed the analysts' consensus estimate of $0.77 by $0.02 with a reported earnings per share (EPS) of $0.75. Learn more on analysts' earnings estimate vs. HALO's actual earnings. How much revenue does Halozyme Therapeutics generate each year? Halozyme Therapeutics (NASDAQ:HALO) has a recorded annual revenue of $829.25 million. How much profit does Halozyme Therapeutics generate each year? Halozyme Therapeutics (NASDAQ:HALO) has a recorded net income of $281.59 million. HALO has generated $2.11 earnings per share over the last four quarters. What is Halozyme Therapeutics's price-to-earnings ratio? Halozyme Therapeutics (NASDAQ:HALO) has a trailing price-to-earnings ratio of 19.28 and a forward price-to-earnings ratio of 12.22. The price/earnings-to-growth ratio is 0.48. What is Halozyme Therapeutics's EPS forecast for next year? Halozyme Therapeutics's earnings are expected to grow from $3.33 per share to $4.18 per share in the next year, which is a 25.53% increase. More Earnings Resources from MarketBeat Related Companies: EXEL Earnings Date RLAY Earnings Date ALLO Earnings Date FATE Earnings Date NVAX Earnings Date ADPT Earnings Date KOD Earnings Date RGEN Earnings Date NBIX Earnings Date RVMD Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Lululemon Stock Implodes Post Earnings, Guidance Muted Applied Optoelectronics earnings dumper, pain now for gain later?Is Roku worth a second look after the earnings panic selloff?Dell Technologies breaks out ahead of earnings releaseNovavax’s dispute resolution and upcoming earnings callImpinj stock surges on strong earnings and guidanceAirbnb stock bulls just went all in before earnings This page (NASDAQ:HALO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.